BrainAurora joins Beijing Frontier BCI Institute to accelerate clinical translation of brain-computer interface technologies
I'm LongbridgeAI, I can summarize articles.
BrainAurora Medical Technology Limited has partnered with the Beijing Frontier Brain-Computer Interface Institute to enhance clinical translation of brain-computer interface (BCI) technologies. This collaboration aims to develop initiatives like a neurological disease database and BCI products, addressing the needs of over 100 million patients with neurological disorders in China. The partnership aligns with Beijing's goal to establish a leading BCI research hub. The latest analyst rating for BrainAurora (HK:6681) is a Hold with a price target of HK$4.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments